Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Conditions: Relapsed Ovarian Cancer Interventions: Drug: Fluzoparib; Drug: Apatinib Sponsors: Jin Li Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Milestone for Company’s lead peptide-drug conjugate candidate follows FDA acceptance of protocol amendment for Phase 1 study on June 2, 2023
MONTREAL, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 12, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Conditions: Low Grade Serous Ovarian Cancer Interventions: Drug: avutometinib + defactinib; Drug: Investigator Choice of Treatment (ICT) Sponsors: Verastem, Inc.; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS
Conditions: Ovarian Cancer Interventions: Procedure: Blood samples Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
Conditions: Recurrent Ovarian Cancer Sponsors: Power Life Sciences Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer
Conditions: Epithelial Ovarian Cancer Interventions: Other: Biological sample collection Sponsors: Exscientia GmbH; AGO Research GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
Conditions: Ovarian Clear Cell Carcinoma Interventions: Drug: Dostarlimab; Drug: LB-100 Sponsors: M.D. Anderson Cancer Center; GSK Pharma; Lixte Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Conditions: Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovarian Carcinoma; BRCA-Associated Breast Carcinoma; HRD Positive Advanced Ovarian Cancer Interventions: Drug: TNG348; Drug: Olaparib Sponsors: Tango Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction
Conditions: Ovarian Cancer Interventions: Procedure: Tumor biopsy Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145
Conditions: Ovarian Cancer Interventions: Drug: KAND145; Drug: Placebo Sponsors: Kancera AB; LINK Medical Research AB; Q&Q Labs AB; CRST Oy Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Conditions: Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; High Grade Endometrioid Ovarian Cancer; Primary Peritoneal Cancer; Fallopian-tube Cancer Interventions: Drug: Fluzoparib Capsules; Drug: Bevacizumab Sponsors: Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Conditions: Serous Ovarian Cancer; Advanced Ovarian Cancer Interventions: Drug: SC0191; Drug: Gemcitabine; Drug: Paclitaxel Sponsor: Biocity Biopharmaceutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Conditions: Serous Ovarian Cancer; Advanced Ovarian Cancer Interventions: Drug: SC0191; Drug: Gemcitabine; Drug: Paclitaxel Sponsors: Biocity Biopharmaceutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
